Stay updated on Galcanezumab in Chronic Migraine Ages 12-17 Clinical Trial

Sign up to get notified when there's something new on the Galcanezumab in Chronic Migraine Ages 12-17 Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Galcanezumab in Chronic Migraine Ages 12-17 Clinical Trial page

  1. Check
    4 days ago
    No Change Detected
  2. Check
    11 days ago
    Change Detected
    Summary
    The page’s display revision was updated from v3.5.2 to v3.5.3, reflecting a site/version update rather than any modification to the clinical trial record itself.
    Difference
    0.0%
    Check dated 2026-04-23T21:57:05.000Z thumbnail image
  3. Check
    18 days ago
    Change Detected
    Summary
    The page now displays Revision: v3.5.2, replacing the previous Revision: v3.5.0.
    Difference
    0.0%
    Check dated 2026-04-16T12:36:11.000Z thumbnail image
  4. Check
    26 days ago
    No Change Detected
  5. Check
    47 days ago
    Change Detected
    Summary
    Added Revision: v3.5.0 and removed Revision: v3.4.3 from the study record history.
    Difference
    0.0%
    Check dated 2026-03-18T23:01:15.000Z thumbnail image
  6. Check
    54 days ago
    Change Detected
    Summary
    New site revision entry v3.4.3 added to the history, replacing the previous v3.4.2 entry.
    Difference
    0.0%
    Check dated 2026-03-11T19:57:59.000Z thumbnail image
  7. Check
    61 days ago
    Change Detected
    Difference
    0.2%
    Check dated 2026-03-04T16:14:17.000Z thumbnail image
  8. Check
    83 days ago
    Change Detected
    Summary
    A new site revision (v3.4.2) was added and an old government funding notice was removed; these are site-wide UI updates and do not affect study data. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.3%
    Check dated 2026-02-11T09:27:00.000Z thumbnail image

Stay in the know with updates to Galcanezumab in Chronic Migraine Ages 12-17 Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Galcanezumab in Chronic Migraine Ages 12-17 Clinical Trial page.